Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Authors

Nusayba Bagegni, Washington University School of Medicine in St. Louis
Shana Thomas, Washington University School of Medicine in St. Louis
Ning Liu, Washington University School of Medicine in St. Louis
Jingqin Luo, Washington University School of Medicine in St. Louis
Jeremy Hoog, Washington University School of Medicine in St. Louis
Donald W. Northfelt, Mayo Clinic
Matthew P. Goetz, Mayo Clinic
Andres Forero, University of Alabama at Birmingham
Matthias Bergqvist, Biovica International AB
Jakob Karen, Pelago Bioscience AB
Magnus Neumuller, Biovica International AB
Edward M. Suh, Biovica International AB
Zhanfang Guo, Washington University School of Medicine in St. Louis
Kiran Vij, Washington University School of Medicine in St. Louis
Souzan Sanati, Washington University School of Medicine in St. Louis
Matthew Ellis, Baylor College of Medicine
Cynthia X. Ma, Washington University School of Medicine in St. Louis

Journal

Breast Cancer Research

Publication Date

2017

Volume

19

Inclusive Pages

123

Document Type

Open Access Publication

DOI

10.1186/s13058-017-0913-7

Rights and Permissions

Bagegni et al. Breast Cancer Research (2017) 19:123 DOI 10.1186/s13058-017-0913-7

Recommended Citation

Bagegni, Nusayba; Thomas, Shana; Liu, Ning; Luo, Jingqin; Hoog, Jeremy; Northfelt, Donald W.; Goetz, Matthew P.; Forero, Andres; Bergqvist, Matthias; Karen, Jakob; Neumuller, Magnus; Suh, Edward M.; Guo, Zhanfang; Vij, Kiran; Sanati, Souzan; Ellis, Matthew; and Ma, Cynthia X., "Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib." Breast Cancer Research. 19, 123. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6475